Comparative Pharmacology
Head-to-head clinical analysis: LISDEXAMFETAMINE DIMESYLATE versus METADATE CD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LISDEXAMFETAMINE DIMESYLATE versus METADATE CD.
LISDEXAMFETAMINE DIMESYLATE vs METADATE CD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lisdexamfetamine is a prodrug of dextroamphetamine, which blocks the reuptake of norepinephrine and dopamine from the synaptic cleft and increases their release into the extraneuronal space.
Methylphenidate is a central nervous system (CNS) stimulant. It blocks the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their levels in the extraneuronal space. The precise mechanism for treating ADHD is not fully understood.
30–70 mg orally once daily in the morning.
20-60 mg orally once daily in the morning
None Documented
None Documented
Terminal elimination half-life of lisdexamfetamine is approximately 1 hour (prodrug conversion), while dextroamphetamine (active moiety) has a half-life of 10-12 hours in adults. In children, half-life is slightly shorter (9-11 hours). Clinically, once-daily dosing provides symptom control for ADHD.
Terminal elimination half-life: 6.8 hours (range 4.5-10.3 hours) for methylphenidate; clinical context: supports twice-daily dosing regimen
Primarily renal: approximately 95% of the dose is excreted in urine, with about 70% as intact lisdexamfetamine, 20% as dextroamphetamine and its metabolites (hippuric acid, benzoic acid), and minimal biliary/fecal elimination (<5%).
Renal: 78-97% as metabolites (primarily ritalinic acid), unchanged drug <1%; fecal: <2%
Category C
Category C
CNS Stimulant
CNS Stimulant